NASDAQ:LOXO - Loxo Oncology Stock Price, News, & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$234.66Today's Range$234.66 - $234.6652-Week Range$101.70 - $234.93Volume400 shsAverage Volume565,561 shsMarket Capitalization$7.18 billionP/E RatioN/ADividend YieldN/ABeta2.51 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut. Receive LOXO News and Ratings via Email Sign-up to receive the latest news and ratings for LOXO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LOXO Previous Symbol CUSIPN/A CIK1581720 Webhttp://www.loxooncology.com/ Phone203-653-3880Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.62Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$21.30 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$12.63 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($5.31) Net Income$-148,870,000.00 Net Margins-43.49% Return on Equity-16.42% Return on Assets-8.66%Miscellaneous EmployeesN/A Outstanding Shares30,610,000Market Cap$7.18 billion Next Earnings DateN/A OptionableOptionable Loxo Oncology (NASDAQ:LOXO) Frequently Asked Questions What is Loxo Oncology's stock symbol? Loxo Oncology trades on the NASDAQ under the ticker symbol "LOXO." How were Loxo Oncology's earnings last quarter? Loxo Oncology Inc (NASDAQ:LOXO) released its earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.15. The biopharmaceutical company had revenue of $42.60 million for the quarter, compared to the consensus estimate of $32.36 million. Loxo Oncology had a negative net margin of 43.49% and a negative return on equity of 16.42%. During the same period in the previous year, the firm earned ($0.94) EPS. View Loxo Oncology's Earnings History. What price target have analysts set for LOXO? 13 brokers have issued 1-year price objectives for Loxo Oncology's shares. Their predictions range from $165.00 to $235.00. On average, they anticipate Loxo Oncology's stock price to reach $204.00 in the next twelve months. View Analyst Price Targets for Loxo Oncology. What is the consensus analysts' recommendation for Loxo Oncology? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Loxo Oncology in the last year. There are currently 6 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Loxo Oncology. What are Wall Street analysts saying about Loxo Oncology stock? Here are some recent quotes from research analysts about Loxo Oncology stock: 1. JMP Securities analysts commented, "We view the success of larotrectinib as a crucial step in the paradigm shift we see occurring in the treatment landscape for oncology toward biomarker-driven drug development. Further, we consider the FDA’s support of larotrectinib, which has benefited from expedited development in the U.S. due to its breakthrough therapy status and accelerated approval pathways, as signaling the agency’s commitment to ushering in a new era of targeted medicines in oncology." (11/29/2018) 2. According to Zacks Investment Research, "Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. " (11/16/2018) 3. Citigroup Inc analysts commented, "Enbrel treats rheumatoid arthritis and related diseases and is a major contributor to Amgen’s sales and growth. We currently estimate that Enbrel sales in the psoriatic arthritis (PsA) setting account for 13% of total Enbrel sales in 2018. Enbrel’s overall market penetration likely will moderate due to completion from biosimilars outside the US and potentially in the US. We anticipate Enbrel sales to decline by approximately 6% per year from 2017-2022, but will still account for 12% of sales by 2022. However, these data presented today at ACR in PA could lead to increased adoption in the setting and provide upside to our outlook." (10/24/2018) Has Loxo Oncology been receiving favorable news coverage? News coverage about LOXO stock has trended negative on Friday, InfoTrie reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Loxo Oncology earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. Who are some of Loxo Oncology's key competitors? Some companies that are related to Loxo Oncology include Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE) and Alnylam Pharmaceuticals (ALNY). What other stocks do shareholders of Loxo Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Loxo Oncology investors own include Alibaba Group (BABA), Netflix (NFLX), NVIDIA (NVDA), Canopy Growth (CGC), GW Pharmaceuticals PLC- (GWPH), Celgene (CELG), Advanced Micro Devices (AMD), Sarepta Therapeutics (SRPT), Micron Technology (MU) and Exelixis (EXEL). Who are Loxo Oncology's key executives? Loxo Oncology's management team includes the folowing people: Dr. Joshua H. Bilenker, Founder, Pres, CEO & Director (Age 47)Ms. Jennifer Burstein M.B.A. CPA, Sr. VP of Fin. (Age 47)Mr. Jacob S. Van Naarden, Chief Operating Officer (Age 34)Ms. Jennifer L. Kronick, VP of HRDr. Nisha Nanda, Chief Devel. Officer (Age 44) How big of a company is Loxo Oncology? Loxo Oncology has a market capitalization of $0.00 and generates $21.30 million in revenue each year. The biopharmaceutical company earns $-148,870,000.00 in net income (profit) each year or ($5.31) on an earnings per share basis. What is Loxo Oncology's official website? The official website for Loxo Oncology is http://www.loxooncology.com/. How can I contact Loxo Oncology? Loxo Oncology's mailing address is 281 TRESSER BOULEVARD 9TH FLOOR, STAMFORD CT, 06901. The biopharmaceutical company can be reached via phone at 203-653-3880 or via email at [email protected] MarketBeat Community Rating for Loxo Oncology (NASDAQ LOXO)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 352 (Vote Outperform)Underperform Votes: 239 (Vote Underperform)Total Votes: 591MarketBeat's community ratings are surveys of what our community members think about Loxo Oncology and other stocks. Vote "Outperform" if you believe LOXO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LOXO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: What is the strike price in options trading? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.